Compare Repligen Corporation Common Stock (RGEN) vs Westinghouse Air Brake Technologies Corporation Common Stock (WAB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Westinghouse Air Brake Technologies Corporation Common Stock — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Westinghouse Air Brake Technologies Corporation Common Stock trades at $286.02 (market cap $48.39B). The key difference: Westinghouse Air Brake Technologies Corporation Common Stock is far larger — about 4.3× Repligen Corporation Common Stock's market cap, and Westinghouse Air Brake Technologies Corporation Common Stock pays a 0.43% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Westinghouse Air Brake Technologies Corporation Common Stock for 0 Days on average.
| RGEN | WAB | |
|---|---|---|
Market Cap | $11.14B | $48.39B |
Volume | 1,259,263 | 960,464 |
Sector | Health | Industrials |
52-Week High | $194.57 | $305.79 |
52-Week Low | $102.87 | $193.43 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $11.02B | $54.30B |
Dividend Yield | — | 0.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Wabtec (WAB) trades at $286.51, up 0.26% today, with a neutral technical signal. The company shows strong fundamentals, with Q2 2026 EPS of $2.76 beating estimates and revenue growth to $12.0B projected for 2026. A $700M+ African rail services deal and raised full-year guidance highlight positive business momentum. Key support rests at $284, with resistance at $288.
The outlook is positive, driven by earnings beats, margin expansion, and a robust backlog. Risks include premium valuation (P/E 38.56) and investing cash outflows. Analyst consensus is bullish with a $326.50 price target, suggesting ~14% upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Westinghouse Air Brake Technologies Corporation Common Stock
Westinghouse Air Brake Technologies Corporation, known as Wabtec, provides equipment, systems, and services for the freight rail and passenger transit industries. Its Freight segment supplies locomotives, braking systems, and signaling technology, while its Transit segment supports passenger rail systems worldwide.
Read more on WAB →
